The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2023

Filed:

Mar. 08, 2019
Applicant:

Agenus Inc., Lexington, MA (US);

Inventors:

Nicholas Stuart Wilson, San Carlos, CA (US);

Jeremy Dale Waight, Everett, MA (US);

Shawn Michael Jennings, Acton, MA (US);

Olga Ignatovich, Cambridge, GB;

Emmanuel Cyrille Pascal Briend, Cambridge, GB;

Benjamin Maxime Morin, Somerville, MA (US);

Oliver Schon, Cambridge, GB;

Spencer Campbell, Essex, GB;

Assignee:

AGENUS INC., Lexington, MA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/71 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01);
Abstract

The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGFβ-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.


Find Patent Forward Citations

Loading…